Customer reviews for Optimi Health Corp.

No reviews yet. Share the first one.

Optimi Health Corp.

Psychedelic medicine developer

Optimi Health Corp. develops and manufactures finished-dose, naturally derived psilocybin and MDMA products for regulated programs. Its pipeline includes a Health Canada-authorized Phase 2 psilocybin study for major depressive disorder planned to begin in 2027 and a Health Canada-authorized Phase 3 MDMA trial for PTSD announced in 2026. The company is listed as active and based in Princeton, British Columbia; no ownership changes are specified in the available information. Its candidates are investigational and are not available to buy.

Website
optimi.net

Optimi Health Corp. catalog

All products · Psychedelic medicine pipeline

Shop the Optimi Health Corp. catalog

2 items across 1 shelf

Psychedelic medicine pipeline2 items